Funding Roundup: Kanvas Biosciences, LTZ Therapeutics Draw Investor Interest for Next-Generation Cancer Immunotherapies

Investor appetite for differentiated oncology platforms remained active this week as two emerging biotechnology companies—Kanvas Biosciences and LTZ Therapeutics—announced significant financing rounds aimed at accelerating next-generation cancer immunotherapy programs.

Together, the companies raised $86 million to support clinical development activities and expand platform capabilities in microbiome therapeutics and myeloid cell-directed immunotherapies, two areas attracting increasing scientific and commercial interest within oncology drug development.

Kanvas Advances Microbiome-Based Cancer Therapies

Kanvas Biosciences announced the close of a $48 million Series A financing round to advance its live biotherapeutic product platform and move its lead oncology candidate, KAN-001, into clinical development. The financing was co-led by DCVC and Lions Capital LLC, with participation from investors including the Gates Foundation, ATHOS KG, Germin8, Ki Tua Fund, and Pangaea Ventures.²

The Princeton, NJ-based company is focused on engineering microbiome-based therapeutics using spatial biology technologies that map interactions between microbial and host cells. According to the company, the platform is designed to address longstanding challenges in microbiome drug development, including demonstrating engraftment and identifying functionally relevant microbial consortia.²

Kanvas said proceeds from the financing will support clinical trials for KAN-001, an immuno-oncology candidate intended to improve responses to immune checkpoint inhibitors in solid tumor patients. The company noted that although checkpoint inhibitors are widely used across oncology, only a subset of patients achieve durable responses, leaving a substantial unmet medical need.³

In addition to KAN-001, the company disclosed ongoing Phase 1 operational activities for KAN-004, a candidate targeting checkpoint inhibitor-induced colitis. The financing brings Kanvas’ total capital raised to approximately $78 million.

Interest in microbiome therapeutics has continued to grow as researchers increasingly examine the relationship between the gut microbiome and immunotherapy efficacy. Several studies have suggested that microbial composition may influence tumor microenvironment activity and treatment outcomes, further fueling investment in the space.¹

LTZ Therapeutics Targets Innate Immunity

Meanwhile, LTZ Therapeutics announced a $38 million financing round to support development of its myeloid engager immunotherapy pipeline. The company is developing therapies designed to activate innate immune cells, including macrophages and other myeloid cell populations, to improve anti-tumor responses.

The financing will be used to advance preclinical and translational development programs and further expand the company’s engager platform technology, according to the company announcement.⁴

Myeloid-targeted immunotherapies have become an increasingly prominent area within oncology R&D as developers look beyond traditional T-cell engager approaches. Researchers have focused on the tumor microenvironment and innate immune modulation as potential avenues to overcome resistance mechanisms associated with current immunotherapies.

Industry analysts have noted that investor support for platform-based oncology companies remains comparatively resilient, particularly for technologies addressing immunotherapy resistance or difficult-to-treat solid tumors. The financings by Kanvas and LTZ reflect continued confidence in emerging therapeutic modalities capable of expanding the reach of precision immuno-oncology.

Oncology Innovation Continues to Attract Capital

Although biotech financing conditions remain selective, oncology continues to represent one of the strongest therapeutic areas for venture investment. Companies with differentiated platform technologies and clear translational strategies have generally maintained access to capital, particularly when targeting major unmet needs in solid tumors and immunotherapy response.

The recent financings suggest investors remain willing to back early-stage companies pursuing novel mechanisms that could complement or improve existing cancer treatment paradigms.

References

1. Chakraborty, D., Ivan, C., Amero, P., Khan, M., Rodriguez-Aguayo, C., Başağaoğlu, H., & Lopez-Berestein, G. (2021 Apr 24). Explainable artificial intelligence reveals novel insight into tumor microenvironment conditions linked with better prognosis in patients with breast cancer. arXiv. https://arxiv.org/abs/2104.12021
   
2. Kanvas Biosciences secures $48M Series A to deliver novel microbiome therapeutics to cancer patients. (2026, May 6). Business Wire. https://www.businesswire.com/news/home/20260506062784/en/Kanvas-Biosciences-Secures-%2448M-Series-A-to-Deliver-Novel-Microbiome-Therapeutics-to-Cancer-Patients
   
3. MedPath. (2026, May 7). Kanvas Biosciences raises $48M Series A to advance microbiome-based cancer immunotherapy. https://trial.medpath.com/news/kanvas-biosciences-raises-48m-series-a-to-advance-microbiome-based-cancer-immunotherapy 
   
4. LTZ Therapeutics raises $38 million in support of advancing myeloid engager immunotherapy pipeline. (2026, April 28). Business Wire. https://www.businesswire.com/news/home/20260428631901/en/LTZ-Therapeutics-Raises-%2438-Million-in-Support-of-Advancing-Myeloid-Engager-Immunotherapy-Pipeline